VYNE also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. However, the company faces significant headwinds: repibresib missed primary endpoints in Phase 2b vitiligo trials, and VYN202 faced FDA clinical holds related to toxicology concerns. VYNE entered a definitive all-stock merger with Yarrow Bioscience, with the combined company expected to operate as Yarrow Bioscience and trade on Nasdaq as YARW, with RTW Investments committing approximately $200 million in pre-closing financing.
Cyborg Score Rationale
VYNE faces critical development setbacks with repibresib missing Phase 2b primary endpoints and VYN202 encountering FDA clinical holds. The company's pipeline is severely constrained, and it is being acquired by Yarrow Bioscience. With minimal cash runway and mounting losses, execution risk is very high.
Top Insights
Repibresib (VYN201) Phase 2b vitiligo trial failed primary and key secondary endpoints; company terminating extension phase and seeking external partnership
VYN202 faced FDA partial clinical hold due to testicular toxicity in preclinical studies, but FDA partially lifted hold for female patients with promising preliminary efficacy data
Definitive merger agreement with Yarrow Bioscience announced December 2025; combined entity to trade as YARW with $200M+ committed financing extending runway into 2028
Company initiating strategic review in August 2025 to evaluate partnerships, licensing, and asset sales; significant R&D cost reduction underway
Named Competitors
Pan-BET Inhibitors — Competitive mechanism class for inflammatory diseases
Topical Inflammatory Treatments — Established market for vitiligo and dermatologic conditions
Oral BD2-Selective BET Inhibitors — Emerging mechanism for systemic inflammatory conditions
Recent Developments
(December 2025) All-stock merger agreement with Yarrow Bioscience announced; combined company to trade as YARW
(November 2025) Q3 2025 results: $32.7M cash runway; net loss of $7.3M; R&D spending down 48.7% YoY